Related Experiment Video

Updated: Aug 10, 2026

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs
08:13

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Published on: December 27, 2016

Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells

S Muthukkumar1, T M Ramesh, S Bondada

  • 1Department of Microbiology and Immunology, University of Kentucky, Lexington 40536-0230, USA.

Transplantation
|August 15, 1995
PubMed

Insights

Rapamycin significantly inhibits lymphoma and thymoma cell growth by inducing apoptosis. This immunosuppressive drug shows potential for preventing lymphoma after organ transplantation.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Rapamycin is a potent immunosuppressive drug used to prevent organ transplant rejection.
  • Lymphoma and thymoma are types of cancer affecting immune cells.
  • Understanding drug mechanisms is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the effect of rapamycin on lymphoma and thymoma cell growth.
  • To determine the mechanism of rapamycin-induced cell death.
  • To explore the interaction of rapamycin with other immunosuppressants like FK506 and Cyclosporin A (CsA).

Main Methods:

  • Treatment of various lymphoma and thymoma cell lines with rapamycin, FK506, and CsA.
  • Assessment of cell growth inhibition and induction of apoptosis.
  • Evaluation of synergistic effects with anti-IgM antibodies and reversal by FK506.

Main Results:

  • Rapamycin caused profound growth inhibition and apoptosis in B cell lymphoma (BKS-2) and thymoma cells at low concentrations.
  • FK506 antagonized rapamycin's effect, rescuing cells from apoptosis, while CsA did not.
  • Rapamycin and anti-IgM antibodies showed synergistic growth inhibition, reversible by FK506, suggesting rapamycin binds to FK506 binding protein.

Conclusions:

  • Rapamycin effectively inhibits lymphoma and thymoma cell growth through apoptosis.
  • Rapamycin's mechanism involves binding to FK506 binding protein.
  • Rapamycin warrants evaluation as a therapeutic agent to prevent post-transplant lymphoma.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...